Payment overview · 2025
General Payments
$89,482.81
386 reported records · 42 companies
Healthcare provider profile · identity verified
Ryan Stuart Drake, DO
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CANTON, OH · NPI 1326256462
Verified facts
What the public records show
CMS Open Payments records show Ryan Stuart Drake, DO received $89,482.81 in general payments during 2025 across 386 reported records.
Lilly USA, LLC accounted for 93.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 56 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Botox, Briviact, Ingrezza, Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ongentys by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xcopri by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Austedo Xr by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $83,786.72 | 93.6% | 85 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,011.68 | 1.1% | 63 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $447.56 | 0.5% | 18 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$406.91 | 0.5% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $370.54 | 0.4% | 26 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $279.63 | 0.3% | 8 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $241.31 | 0.3% | 15 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $237.71 | 0.3% | 18 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $231.72 | 0.3% | 13 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $228.56 | 0.3% | 16 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $211.58 | 0.2% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $179.83 | 0.2% | 8 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $168.04 | 0.2% | 8 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $154.41 | 0.2% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.21 | 0.2% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $132.32 | 0.1% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $122.30 | 0.1% | 7 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $90.17 | 0.1% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $88.48 | 0.1% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $87.94 | 0.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $79.84 | 0.1% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $68.34 | 0.1% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $67.48 | 0.1% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $66.99 | 0.1% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$66.93 | 0.1% | 3 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $66.23 | 0.1% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $65.54 | 0.1% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.27 | 0.1% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $44.32 | 0.1% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $42.19 | 0.1% | 3 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $33.77 | 0.0% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.45 | 0.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $28.78 | 0.0% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.70 | 0.0% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $23.87 | 0.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $16.90 | 0.0% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $16.47 | 0.0% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $14.78 | 0.0% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $14.31 | 0.0% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.07 | 0.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.03 | 0.0% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.93 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $72,075.00 | 46 |
| Travel and Lodging | $10,352.51 | 16 |
| Food and Beverage | $6,926.68 | 322 |
| Education | $128.62 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $73,396.14 | 67 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $624.27 | 46 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $508.57 | 30 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $355.52 | 25 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $348.36 | 24 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $285.40 | 11 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $241.31 | 15 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $237.71 | 18 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $231.72 | 13 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $217.71 | 22 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $211.58 | 9 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $183.29 | 7 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $168.04 | 8 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $154.41 | 6 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $151.08 | 7 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $122.30 | 7 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $101.42 | 5 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $93.79 | 6 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $90.17 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $82.27 | 3 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $80.45 | 4 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $79.84 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $74.45 | 4 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $72.61 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $69.04 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $68.34 | 4 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $67.48 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $66.93 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $66.65 | 3 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $66.23 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $65.54 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $57.87 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $50.27 | 3 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $44.32 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $43.15 | 2 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $33.77 | 2 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $33.77 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $31.45 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $28.94 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $28.78 | 2 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| RYTARY Normalized: rytary |
Drug | Amneal Pharmaceuticals LLC | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $12.76 | 1 | 2025 |
Source payment records
|
|||||
| BREKIYA Normalized: brekiya |
Drug | Amneal Pharmaceuticals LLC | $12.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| BOTOX botox |
2025 | Botox | 2024 | 86 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 44 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 57 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
86 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
57 | 22 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 377 | 110 |
| Donepezil Hcl | Donepezil Hcl | 354 | 120 |
| Levetiracetam | Levetiracetam | 335 | 105 |
| Memantine Hcl | Memantine Hcl | 334 | 98 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 333 | 116 |
| Topiramate | Topiramate | 184 | 60 |
| Amitriptyline Hcl | Amitriptyline Hcl | 175 | 57 |
| Primidone | Primidone | 149 | 42 |
| Pregabalin | Pregabalin | 133 | 37 |
| Baclofen | Baclofen | 99 | 28 |
| Botox | Onabotulinumtoxina | 86 | 30 |
| Propranolol Hcl Er | Propranolol Hcl | 85 | 30 |
| Divalproex Sodium | Divalproex Sodium | 82 | 31 |
| Rizatriptan | Rizatriptan Benzoate | 75 | 27 |
| Zonisamide | Zonisamide | 74 | 23 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 72 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 71 | 20 |
| Divalproex Sodium Er | Divalproex Sodium | 67 | 14 |
| Lacosamide | Lacosamide | 67 | 13 |
| Carbamazepine Er | Carbamazepine | 65 | 17 |
| Prednisone | Prednisone | 65 | 21 |
| Aimovig Autoinjector | Erenumab-Aooe | 62 | 13 |
| Azathioprine | Azathioprine | 59 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 20 |
| Nurtec Odt | Rimegepant Sulfate | 57 | 22 |
| Trazodone Hcl | Trazodone Hcl | 55 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 18 |
| Lamotrigine | Lamotrigine | 53 | 17 |
| Rasagiline Mesylate | Rasagiline Mesylate | 45 | suppressed |
| Briviact | Brivaracetam | 44 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 12 |
| Oxcarbazepine | Oxcarbazepine | 42 | 14 |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 39 | 16 |
| Emgality Pen | Galcanezumab-Gnlm | 39 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 15 |
| Qulipta | Atogepant | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | 11 |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Xcopri | Cenobamate | 26 | suppressed |
| Entacapone | Entacapone | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Ingrezza | Valbenazine Tosylate | 24 | suppressed |
| Ongentys | Opicapone | 24 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 23 | suppressed |
| Austedo Xr | Deutetrabenazine | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 20 | suppressed |
| Austedo | Deutetrabenazine | 18 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Diazepam | Diazepam | 17 | 14 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Carbidopa | Carbidopa | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $89,482.81 · 386 records | Lilly USA, LLC | AMVUTTRA, AMYVID, AUSTEDO XR, BOTOX, BREKIYA, BRIUMVI, Bafiertam, Briviact, CREXONT, DAYBUE, EPIDIOLEX, FYCOMPA, Fintepla, GOMEKLI, Gamunex-C, HYQVIA, INGREZZA, KESIMPTA, KEVEYIS, KISUNLA, LUMRYZ, Leqembi, MOUNJARO, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PONVORY, PRECIVITYAD2, QULIPTA, REXULTI, RYTARY, Radicava, Rystiggo, Sunosi, Symbravo, TRUDHESA, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, WAKIX, XYWAV, ZAVZPRET, ZEPBOUND, Zilbrysq | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error